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Lymphatic vessels share an intimate relationship with hematopoietic cells that commences during embryogenesis
and continues throughout life. Lymphatic vessels provide a key conduit for immune cell trafficking during immune
surveillance and immune responses and in turn, signals produced by immune lineage cells in settings of
inflammation regulate lymphatic vessel growth and activity. In the majority of cases, the recruitment and activation
of immune cells during inflammation promotes the growth and development of lymphatic vessels
(lymphangiogenesis) and enhances lymph flow, effects that amplify cell trafficking to local lymph nodes and
facilitate the mounting of effective immune responses. Macrophages comprise a major, heterogeneous lineage of
immune cells that, in addition to key roles in innate and adaptive immunity, perform diverse tasks important for
tissue development, homeostasis and repair. Here, we highlight the emerging roles of macrophages in
lymphangiogenesis, both during development and in settings of pathology. While much attention has focused on
the production of pro-lymphangiogenic stimuli including VEGF-C and VEGF-D by macrophages in models of
inflammation including cancer, there is ample evidence to suggest that macrophages provide additional signals
important for the regulation of lymphatic vascular growth, morphogenesis and function.
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Macrophages encompass a phenotypically heterogeneous
population of cells that play a rapidly expanding cata-
logue of roles during development, homeostasis and dis-
ease [1-3]. While perhaps best recognised for the key
roles they fulfil in innate and adaptive immunity, macro-
phages (literally “large eaters”, due to their phagocytic
capabilities) also provide apoptosis inducing stimuli im-
portant for tissue remodeling and maturation [4-6], cues
that instruct organ patterning and morphogenesis [7-12]
and signals important for tissue regeneration and repair
[13-15].
Macrophage diversity is obvious both in the embryo
and the adult. In the embryo, macrophage subtypes
can be distinguished on the basis of differential expres-
sion of markers including lymphatic vessel endothelial* Correspondence: natasha.harvey@health.sa.gov.au
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distribution, and reproduction in any mediumhyaluronan receptor (LYVE-1) and the angiopoietin re-
ceptor Tie2 [16,17]. In the adult, distinct populations
of circulating monocytes are categorised as “inflamma-
tory” or “resident” monocytes based on the expression
of markers including Gr1/Ly6C and the chemokine
receptors CX3CR1 and CCR2 [18]. Tie2 has been
reported to mark a distinct lineage of monocytes,
termed Tie2-expressing monocytes (TEMs), that are
recruited to the tumor microenvironment where they
promote the growth of new blood vessels [19]. In re-
sponse to stimuli encountered, monocytes may be
induced to differentiate into macrophage subtypes in-
cluding classically activated, “M1” inflammatory macro-
phages or alternatively activated, “M2” regulatory and
wound healing macrophages. There is little doubt,
however, that the M1 and M2 classification oversimpli-
fies the extent of macrophage heterogeneity [20,21].
Mature, specialist macrophages found in adult tissues
include Kupffer cells of the liver that clear spent ery-
throcytes from the circulation, microglia in the centralCentral Ltd. This is an Open Access article distributed under the terms of the
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osteoclasts in the bone marrow important for bone re-
modeling [1,3].
Recent work has revealed that macrophages play key
roles during vascular development; these include direct-
ing regression of the hyaloid blood vascular plexus
[4,5,22], facilitating the anastomosis of sprouting blood
vessels [10] and patterning the retinal vasculature
[23,24]. Furthermore, macrophages have been shown to
promote neo-vascularization in settings of inflammation
and wound repair by producing pro-angiogenic growth
factors, chemokines and proteases [19,25-27]. In this re-
view, we focus on the roles that macrophages play in
lymphatic vascular growth and development (lymphan-
giogenesis), both during development and in disease.
Developmental origins of macrophages and
lymphatic vessels
The developmental origins of macrophage subsets are
being progressively unravelled, with genetic lineage tra-
cing studies providing answers to longstanding questions
regarding progenitor cell origin and the differentiation
potential of various monocyte/macrophage populations.
Current data suggest that maternally derived macro-
phages are the first to appear in the mouse embryo at ap-
proximately embryonic day (E) 7.5 [28]. Subsequently,
macrophages originating in the yolk sac (E8) and from
definitive hematopoietic progenitor cells arising in the
embryonic aorta-gonad-mesonephros (AGM) (E10.0)
and foetal liver develop (E10.5-onwards) [28]. After birth,
the major site of hematopoiesis is the bone marrow. Re-
cent evidence supports the concept that mature macro-
phages in the adult are derived from distinct progenitor
pools; microglia in the brain appear to be descendents of
primitive myeloid progenitors that arise prior to E8 [29],
while circulating monocytes that give rise to the majority
of tissue macrophages are derived from definitive
hematopoietic stem cells.
Construction of the lymphatic vasculature is initiated
once the major arteries (dorsal aortae) and veins (car-
dinal veins) have been established in the embryo, origin-
ating from the cardinal veins following the onset of
expression of the Prox1 transcription factor in a
polarised population of venous endothelial cells at ~ E9.5
[30]. Prox1-positive lymphatic endothelial progenitor
cells exit the cardinal veins via sprouting and ballooning
mechanisms to form lymph sacs and the superficial
lymphatic vascular plexus [30,31], a process that is
dependent on vascular endothelial growth factor C
(VEGF-C) [32]. The initiation of Prox1 expression in
lymphatic endothelial progenitor cells in the cardinal
veins signifies lymphatic endothelial cell fate commit-
ment and is dependent on the activity of Sox18 and
CoupTFII transcription factors [33,34]. Once established,the lymphatic vasculature regulates tissue fluid homeo-
stasis, immune cell trafficking and the absorption of diet-
ary fats [35,36].
Work in a variety of vertebrate models has suggested
that mesodermal cells, including those of the macro-
phage lineage, might contribute to genesis of the lymph-
atic vasculature during development by comprising a
pool of lymphatic endothelial progenitor cells [37-40].
These studies have suggested that mesenchymal “lym-
phangioblasts” expressing both LEC (Prox1/LYVE-1) and
macrophage markers (LYVE-1, CD45, F4/80) integrate to
growing lymphatic vessels in the developing embryo
[38,40]. In contrast, work from others has concluded that
the vast majority of embryonic lymphatic endothelial
cells are derived from the venous progenitor pool, with
no evidence to support the concept of monocytes or
macrophages giving rise to lymphatic endothelial cells
[17,41]. These discrepancies may potentially be a result
of differences between the vertebrate models employed
in these studies, or of the techniques utilized to assess
macrophage incorporation into lymphatic vessels (mar-
ker expression versus lineage tracing). In fact, embryonic
LYVE-1-positive macrophages have been found to share
an intimate spatial association with embryonic lymphatic
vessels (Figure 1) and in some cases appear incorpor-
ated into the wall of developing lymphatic vessels, but
lineage tracing studies in the mouse embryo have not
detected Prox1 expression in LYVE-1-positive, myeloid
derived cells [17]. This data suggests that these cells
retain a macrophage identity even when resident in
lymphatic vessels. Gene expression profiling of embry-
onic dermal LYVE-1-positive macrophages revealed a
close resemblance to TEMs [16,17], a population of
macrophages that not only play key roles in tumor sti-
mulated angiogenesis, but are important for blood vas-
cular development [10,16,19,42]. These data suggest
that LYVE-1-positive macrophages may be important for
morphogenesis or remodelling of the lymphatic vascula-
ture. Studies utilising real time imaging will be required
to discern whether LYVE-1-positive macrophages assume
localisation in the walls of lymphatic vessels in order to
perform an immune surveillance role, whether they tran-
sit through the lymphatic endothelium while patrolling
the embryo, or whether they fulfil roles important for
lymphatic vascular development.
Macrophages as a source of growth and
patterning signals in developmental
lymphangiogenesis
While it seems unlikely that monocytes/macrophages
comprise a lymphatic endothelial progenitor cell pool
during embryogenesis, recent work from a number of
groups has identified an important role for macrophages
in patterning the lymphatic vasculature. Akin to the role
Figure 1 LYVE-1 positive macrophages share an intimate association with growing lymphatic vessels in embryonic mouse skin. Whole
mount immunostaining of E14.5 skin illustrating the close association of lymphatic vessel filopodia (Nrp2-positive, LYVE-1-positive) with dermal
macrophages (F4/80-positive, LYVE-1-positive). Area boxed in panel A is shown at higher magnification in panel B.
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of sprouting blood vessels in the embryonic brain [10]
and postnatal retina [23], work from Kubota and collea-
gues suggested that LYVE-1-positive macrophages regu-
late density of the lymphatic vasculature in selected
postnatal tissues [43]. Analysis of Csf1op/op mice that lack
a key growth factor for macrophage development, Csf1,
and are therefore severely depleted of macrophages [44],
revealed diminished lymphatic vessel density in the post-
natal trachea [43]. Moreover, depletion of macrophages
using antibodies to c-fms (the receptor for Csf1,
expressed by macrophages), or the small molecule c-fms
tyrosine kinase inhibitor Ki20227, between postnatal day
(P)8 and P15, resulted in reduced lymphatic vessel
branching in the trachea and ears of treated mice. How-
ever, these studies found no evidence of perturbed em-
bryonic lymphangiogenesis in Csf1op/op mice and
lymphatic vascular patterning appeared normal in sur-
viving Csf1op/op mice at 3 months of age [43]. These
observations suggest a temporal window of macrophage
dependence, or potential tissue specific roles, for macro-
phages in developmental lymphangiogenesis.
Work from Bohmer and colleagues demonstrated that
embryonic dermal macrophages expressing the tyrosine
kinase Syk closely resemble TEMs and express high levels
of pro-lymphangiogenic molecules including vascular
endothelial growth factor C (VEGF-C), vascular endothe-
lial growth factor D (VEGF-D), fibroblast growth factor 2
(FGF2), matrix metalloprotease 2 (MMP-2) and matrix
metalloprotease 9 (MMP-9) [45]. In the absence of Syk,
an increased number of these pro-lymphangiogenic
monocytes/macrophages expressing elevated levels of
growth factors and chemokines accumulated in skin and
as a result, Syk−/− embryos displayed hyperplastic dermal
lymphatic vessels. These data suggest that dermal Syk-
expressing macrophages have the potential to promoteembryonic lymphangiogenesis via the production of a
number of pro-lymphangiogenic stimuli. In agreement
with these studies, Gordon and colleagues found that pri-
mary embryonic dermal macrophages promoted the pro-
liferation of primary embryonic dermal LEC when
cultured together ex vivo [17]. Intriguingly though, the
dermal lymphatic vasculature of embryonic PU.1−/− [46]
and Csf1r−/− [47] macrophage deficient mice was found to
be hyperplastic, rather than hypoplastic [17]. These data
suggest that while dermal macrophages have the capacity
to promote lymphangiogenesis via the production of pro-
lymphangiogenic growth factors including VEGF-C and
VEGF-D, they may also act to restrain lymphatic endothe-
lial cell proliferation during development. In contrast to
the dermal lymphatic vasculature, Gordon and colleagues
found that the jugular lymph sacs of embryonic PU.1−/−
mice were smaller than their wild-type littermates, provid-
ing further evidence that macrophages may play distinct,
tissue specific roles during developmental lymphangiogen-
esis [17]. Definitively dissecting the relative contribution
of macrophage-derived signals during developmental lym-
phangiogenesis will rely on the generation of conditional
knockout mice in which genes of interest are inactivated
in a macrophage selective manner.
Macrophages in inflammation and tumor-
stimulated lymphangiogenesis
The roles played by macrophages in pathological lym-
phangiogenesis are rapidly gaining recognition. The in-
duction of lymphangiogenesis during wound healing and
in many pathological settings normally acts to resolve
inflammation and edema; in models of infection and
acute inflammation, increased lymphangiogenesis has
been associated with elevated lymph flow, enhanced im-
mune cell trafficking to draining lymph nodes and the
resolution of tissue inflammation and edema [48-50].
Figure 2 A model depicting the roles of macrophages in
lymphangiogenesis. Macrophages have been proposed to
contribute to lymphangiogenesis by acting as a source of lymphatic
endothelial progenitor cells which incorporate into growing vessels,
or by providing growth and patterning signals such as VEGF-A and
VEGF-C/D, that stimulate the growth and/or function of the
lymphatic vasculature. Lineage tracing studies have suggested that
macrophages do not act as lymphatic endothelial progenitor cells,
yet they share a close spatial localization with lymphatic vessels
during development and express the lymphatic marker LYVE-1.
These macrophages may assume localization in the walls of
lymphatic vessels in order to perform an immune surveillance role,
or be transiting through the lymphatic endothelium. Tumor
associated macrophages (TAMs) and Tie2-expressing monocytes
(TEMs) promote lymphangiogenesis by liberating proteases
important for growth factor activation/matrix remodeling, producing
chemokines that degrade the surrounding extracellular matrix (ECM),
and recruiting additional inflammatory cells.
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lymphangiogenesis induced following organ transplant-
ation has been shown to aid alloimmunization and
thereby promote the rejection of kidney, corneal and
pancreatic islet transplants [51-53]. Understanding how
lymphangiogenesis is regulated during inflammation
thereby stands to advance the development of new ther-
apeutics able to promote or ablate lymphangiogenesis
dependent on the pathological setting.
Macrophages have been demonstrated to drive lym-
phangiogenesis in models of inflammation including
bacterial infection [48,49,54], wound healing [55,56],
organ transplant [57,58], rheumatoid arthritis [59], pan-
creatic islet inflammation/diabetes [60] and atopic
dermatitis [61]. Macrophages also appear to be key
players in salt-induced hypertension, where macrophage
derived VEGF-C is important for inducing lymphangio-
genesis as a buffering mechanism to deal with increased
interstitial fluid accumulation [62]. At least two mechan-
isms by which cells of the monocyte/macrophage lineage
promote neo-lymphangiogenesis have been proposed;
trans-differentiation to lymphatic endothelial cells
[55,57,63-65] and production of pro-lymphangiogenic
stimuli including VEGF-C, VEGF-D and VEGF-A
[48,49,54,66-68] (Figure 2). The relative contribution
that macrophages provide to inflammation-stimulated
lymphangiogenesis has been illustrated in studies of
macrophage deficient mice [43] and by the depletion of
macrophages using clodronate liposomes [49,67], c-fms
inhibition [43] or VEGF-A inhibition [49,67,69]. VEGF-
C and/or VEGF-D appear to be critical for the pro-
lymphangiogenic activity of macrophages in the majority
of models studied; blockade of VEGF-C and VEGF-D ac-
tivity using soluble VEGFR-3 or VEGFR-3 neutralising
antibodies has been demonstrated to inhibit macrophage
driven lymphangiogenesis [48,49,52,68]. Recent work has
suggested that the extracellular matrix protein
thrombospondin-1 (TSP-1) acts as an endogenous inhibi-
tor of corneal lymphangiogenesis via acting on macro-
phages; ligation of CD36 on the macrophage cell surface
by Tsp-1 was shown to negatively regulate VEGF-C and
VEGF-D production. In the absence of Tsp-1, and in
mice deficient in CD36, precocious lymphangiogenesis
is induced in the cornea [70]. In addition to VEGF fam-
ily members, macrophages are a source of proteases in-
cluding MMP-2 and MMP-9 [1,26,45] that promote
growth factor activation and matrix remodelling, as well
as cytokines and chemokines that recruit additional cells
of the immune system. Immune cells including granulo-
cytes, B and T lymphocytes have also been demon-
strated to have pro- and anti lymphangiogenic activities
[48,71-73] and their capacity to regulate lymphangio-
genesis should be taken into account when looking at
the “big picture” of inflammation.Many studies have shown that the growth of lymphatic
vessels in the tumor microenvironment facilitates tumor
metastasis [74]. Tumor-stimulated lymphangiogenesis
often results in the formation of abnormal, leaky lymph-
atic vessels, a feature that provides metastatic tumor
cells with ready access to the lymphatic vasculature
[75,76]. Macrophage recruitment to tumors has been
demonstrated to promote lymphangiogenesis in a variety
of mouse tumor models [43,66,68,77,78] and tumor
associated macrophages (TAMs) have been linked with
increased peri-tumoral lymphangiogenesis and metasta-
sis in human cancers including breast cancer [79], cer-
vical cancer [66], squamous cell carcinoma [80] and
advanced colorectal cancer [81]. In a mouse model of
osteosarcoma, inhibition of Csf1 diminished macrophage
recruitment to the tumor environment, suppressed
tumor angiogenesis and lymphangiogenesis and reduced
tumor metastasis [43]. Similarly, in a model of urinary
bladder cancer, depletion of TAMs with clodronate lipo-
somes and suppression of lymphangiogenesis with sol-
uble VEGFR-3 inhibited lymphangiogenesis and tumor
metastasis [77]. Studies such as these suggest that thera-
peutics designed to block macrophage influx or inhibit
macrophage activity might provide valuable anti-tumor
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growth of new lymphatic vessels in the vicinity of
tumors, macrophage derived pro-lymphangiogenic
growth factors including VEGF-C and VEGF-D may act
downstream of the initial lymphatics on collecting ves-
sels to promote their dilation and capacity for lymph
flow, thereby facilitating metastatic tumor cell transport
[35,82]. TAMs may also contribute to lymphangiogenesis
associated pathologies in addition to aiding metastasis.
When a metastatic human ovarian cancer cell line was
transplanted into mice, Jeon and colleagues found that
tumor progression was associated with the development
of chylous ascites due to a profound dysfunctional lym-
phangiogenic response [68]. Blockade of VEGF-C/-D
with soluble VEGFR-3 and of VEGF-A signaling with
VEGF-Trap prevented the formation of chylous ascites,
implicating macrophage derived VEGF-C/-D in ascites
development due to the failure of aberrant lymphatic
vessels to mediate fluid clearance from the peritoneal
cavity [68]. This study has implications for the treatment
of ascites in ovarian cancer patients.Perspectives and future directions
A growing body of data now cements “regulation of lym-
phangiogenesis during development and disease” to-
gether with the plethora of important roles that
macrophages play in tissue morphogenesis, homeostasis,
repair and immunity. Many questions remain to be
answered before we will completely understand how
macrophages regulate lymphangiogenesis. Current top-
ical questions include: What is the relative contribution
of macrophage derived VEGF-C and -D to embryonic
and inflammation stimulated lymphangiogenesis? What
signals in addition to VEGF family members do macro-
phages provide that control lymphatic vascular growth
and morphogenesis? Do different macrophage subtypes
differ with respect to their pro- or anti- lymphangiogenic
activity? The generation of new experimental tools in-
cluding genetically modified mice and agents able to spe-
cifically track and manipulate macrophage sub-types will
be important for advancing these studies. Though the
blockade of macrophages and/or macrophage derived
factors poses an attractive strategy for anti-inflammatory
and anti-tumor therapies, it will first be important to
determine the precise roles of these intriguing cells in
developmental and pathological lymphangiogenesis.Competing interests
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